Compare ADMA Biologics Inc (ADMA) vs Dover Corp (DOV) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Dover Corp — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Dover Corp trades at $211.06 (market cap $28.82B). The key difference: Dover Corp is far larger — about 13.5× ADMA Biologics Inc's market cap, and Dover Corp pays a 0.97% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | DOV | |
|---|---|---|
Market Cap | $2.13B | $28.82B |
Sector | Health | Industrials |
52-Week High | $20.38 | $233.31 |
52-Week Low | $7.60 | $161.16 |
Enterprise Value | $2.20B | $30.47B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Dover Corporation (DOV) trades at $214.05, up 0.16% on the day, with a bearish technical signal but strong fundamentals including a 13.3% net income margin and consistent earnings beats. Recent news highlights AI data center demand tailwinds and product launches across its subsidiaries. The stock shows healthy profitability with ROE at 15.06% and a P/E of 26.84, while analyst consensus is bullish with a $251 price target.
Outlook remains positive driven by earnings momentum and AI-related growth, though technical weakness and market volatility pose near-term risks. The stock offers value with a 17% upside to consensus target, supported by dividend payments and institutional confidence, but investors should monitor execution on data center opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →
